Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedApr 16, 2026
DataAggregated Company Financials
Companies547
  • 7D2.0%
  • 3M6.4%
  • 1Y43.3%
  • YTD6.9%

Over the last 7 days, the Biotech industry has risen 2.0%, driven by gains from Revolution Medicines of 58%. This takes the industry's 12 month performance to a gain of 43%. Earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026US$1.3tUS$166.2b-US$11,981,069,450.5917.2x-111.2x8x
Sat, 14 Mar 2026US$1.3tUS$169.1b-US$15,352,346,117.4820.9x-84.6x7.7x
Mon, 09 Feb 2026US$1.3tUS$164.5b-US$14,975,001,086.6922.8x-87.2x7.9x
Wed, 07 Jan 2026US$1.2tUS$163.5b-US$15,343,102,578.7521.5x-78x7.3x
Fri, 05 Dec 2025US$1.2tUS$163.6b-US$16,197,943,349.2419.3x-76.8x7.6x
Sun, 02 Nov 2025US$1.1tUS$162.6b-US$16,488,114,301.1417.7x-69x7x
Tue, 30 Sep 2025US$1.1tUS$163.5b-US$18,299,397,390.1416.5x-58.9x6.6x
Thu, 28 Aug 2025US$1.1tUS$163.6b-US$18,630,669,570.1215.4x-57.1x6.5x
Sat, 26 Jul 2025US$991.0bUS$155.1b-US$22,980,441,196.1914.8x-43.1x6.4x
Mon, 23 Jun 2025US$926.6bUS$155.9b-US$23,867,100,368.6216.8x-38.8x5.9x
Wed, 21 May 2025US$909.2bUS$155.9b-US$24,386,632,960.3815.9x-37.3x5.8x
Fri, 18 Apr 2025US$749.3bUS$119.2b-US$36,618,281,612.0319.4x-20.5x6.3x
Sun, 16 Mar 2025US$838.4bUS$118.4b-US$37,606,321,265.9318.5x-22.3x7.1x
Tue, 11 Feb 2025US$841.4bUS$117.4b-US$36,256,461,776.7617.7x-23.2x7.2x
Thu, 09 Jan 2025US$972.7bUS$149.4b-US$26,292,741,879.8917.2x-37x6.5x
Sat, 07 Dec 2024US$1.0tUS$150.0b-US$26,481,489,967.0117.9x-38.7x6.8x
Mon, 04 Nov 2024US$1.1tUS$147.4b-US$30,522,373,860.5217.6x-35x7.2x
Wed, 02 Oct 2024US$899.5bUS$113.2b-US$35,974,034,598.1221.4x-25x7.9x
Fri, 30 Aug 2024US$906.0bUS$113.1b-US$35,694,070,050.3323.9x-25.4x8x
Sun, 28 Jul 2024US$1.2tUS$164.9b-US$28,965,808,648.7626.4x-43x7.5x
Tue, 25 Jun 2024US$1.2tUS$164.4b-US$27,944,795,069.7428.1x-41.4x7x
Thu, 23 May 2024US$1.1tUS$164.6b-US$26,731,616,038.8524.6x-42.6x6.9x
Sat, 20 Apr 2024US$1.1tUS$164.2b-US$23,337,120,518.7320.4x-45.9x6.5x
Mon, 18 Mar 2024US$1.2tUS$167.4b-US$22,071,849,383.6413.9x-53.2x7x
Wed, 14 Feb 2024US$1.1tUS$168.9b-US$20,817,013,760.7018x-54.6x6.7x
Fri, 12 Jan 2024US$1.4tUS$204.8b-US$22,495,274,678.0019.2x-64.1x7x
Sun, 10 Dec 2023US$1.3tUS$204.6b-US$22,091,414,218.0018.7x-58.3x6.3x
Tue, 07 Nov 2023US$1.2tUS$203.9b-US$22,185,418,652.0018.9x-56x6.1x
Thu, 05 Oct 2023US$1.2tUS$207.3b-US$13,076,809,948.0016.7x-94.9x6x
Sat, 02 Sep 2023US$1.3tUS$207.6b-US$12,424,624,459.0018.4x-104.2x6.2x
Mon, 31 Jul 2023US$1.2tUS$186.0b-US$15,168,211,533.0014.7x-76.1x6.2x
Wed, 28 Jun 2023US$1.1tUS$186.3b-US$16,125,527,732.0013.5x-69.1x6x
Fri, 26 May 2023US$1.1tUS$185.9b-US$15,950,003,280.0011.5x-71.8x6.2x
Sun, 23 Apr 2023US$1.2tUS$198.4b-US$3,214,788,122.0013.9x-370.1x6x
Price to Earnings Ratio

-370.1x


Total Market Cap: US$1.2tTotal Earnings: -US$3,214,788,122.00Total Revenue: US$198.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -60.5x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.8x is lower than the industry's current PS ratio of 8.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Revenues have also declined 5.7% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market3.42%
Healthcare-0.18%
Biotech1.98%
Biotech1.98%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RVMD Revolution MedicinesUS$152.5457.7%
+US$11.1b		321.4%PB18.5x
BNTX BioNTechUS$99.478.0%
+US$1.9b		1.2%PS7.4x
SMMT Summit TherapeuticsUS$21.1212.3%
+US$1.8b		-8.4%PB24.9x
SYRE Spyre TherapeuticsUS$68.9932.7%
+US$1.3b		455.5%PB9.7x
ARWR Arrowhead PharmaceuticalsUS$70.9510.2%
+US$922.8m		525.1%PE49.1x

Latest News

RVMD
US$152.54
Revolution Medicines
7D
57.7%
1Y
321.4%
MRNA
US$54.26
Moderna
7D
4.1%
1Y
115.4%
REGN
US$753.93
Regeneron Pharmaceuticals
7D
-2.8%
1Y
37.3%
BMRN
US$55.27
BioMarin Pharmaceutical
7D
-3.4%
1Y
-6.0%

BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy

Apr 15
SYRE
US$68.99
Spyre Therapeutics
7D
32.7%
1Y
455.5%
NTRA
US$207.19
Natera
7D
-1.7%
1Y
38.0%
AMGN
US$348.22
Amgen
7D
-0.5%
1Y
23.2%

AMGN: Diversified Autoimmune And Cardiovascular Pipeline Will Support Future Cash Generation

Analysts have lifted Amgen's average price target, with changes such as the recent $10, $17, $6, $10 and $15 upward revisions reflecting updated views on its pipeline progress, commercial execution, and refreshed financial models. Analyst Commentary Recent Street research on Amgen shows a cluster of higher price targets and fresh coverage that centers on its pipeline, commercial performance, and updated financial models.
ABBV
US$208.42
AbbVie
7D
-1.5%
1Y
21.4%
BNTX
US$99.47
BioNTech
7D
8.0%
1Y
1.2%
SMMT
US$21.12
Summit Therapeutics
7D
12.3%
1Y
-8.4%
GILD
US$139.77
Gilead Sciences
7D
-1.3%
1Y
33.3%
INSM
US$146.74
Insmed
7D
-8.4%
1Y
109.0%
ROIV
US$29.39
Roivant Sciences
7D
4.3%
1Y
193.3%
VRTX
US$441.70
Vertex Pharmaceuticals
7D
-0.5%
1Y
-9.1%
ARWR
US$70.95
Arrowhead Pharmaceuticals
7D
10.2%
1Y
525.1%

ARWR: RNAi Obesity And Cardiometabolic Data Will Drive Future Repricing

Narrative update on Arrowhead Pharmaceuticals The consensus analyst price target for Arrowhead Pharmaceuticals has been adjusted to $110. This reflects mixed recent research that pairs questions around Wave Life Sciences data with higher targets from several firms citing early obesity program results and the Redemplo launch.
ONC
US$319.94
BeOne Medicines
7D
2.5%
1Y
40.2%

ONC: Hematology Pipeline Strength And Upcoming Data Readouts Will Drive Future Upside

BeOne Medicines' analyst price target has been nudged higher to reflect a fair value estimate of about $408, as analysts balance slightly softer long term growth and margin assumptions with ongoing confidence in Brukinsa and the broader hematology pipeline, including support from several recent target hikes and one downgrade to Hold. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brukinsa as a core value driver, treating it as one of the stronger hematology assets and a key pillar supporting current fair value estimates in the low $400s.